This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer Bolsters Injectables by Buying InnoPharma

NEW YORK (The Deal) -- Fresh from AstraZeneca's (AZN - Get Report) rebuff of its $117 billion offer, Pfizer (PFE - Get Report) is setting its sights on a much smaller deal in the U.S., as the company said Wednesday it will acquire InnoPharma Inc.

Piscataway, N.J.-based InnoPharma is a private drug development company specializing in sterile injectables. Pfizer is paying $225 million cash upfront and has agreed to $135 million in contingent milestones.

InnoPharma has a portfolio of 10 Food and Drug Administration-approved generics and a pipeline of 19 product candidates under FDA review. More than 30 injectable and ophthalmic products are under development at the company.

It is known for producing difficult-to-make products, such as those requiring complex manufacturing capabilities and bio-equivalency challenges, especially in therapeutic areas of cancer and central nervous disorders.

The acquisition would bring New York-based Pfizer's sterile injectables portfolio to 73 products. The deal "is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio," John Young, group president of Pfizer Global Established Pharma, said in a statement. "InnoPharma's technical capabilities in bringing complex generics to market, coupled with its strong talent and product pipeline, build on our efforts to develop and commercialize critically important medicines," he noted.

The transaction is expected to close in the third quarter, subject to regulatory approval.

Pfizer turned to Kaye Scholer LLP for legal advice from a team that included Lowell Dashefsky, Laurie Abramowitz, Jefffrey London, David Barr, Andres Liivak, Aaron Gardner, Irv Hepner, Viktoriya Karshenboyem, Brian Witkowski, Amanda Myers and Connie Ericson.

JPMorgan served as InnoPharma's financial adviser. Morgan, Lewis & Bockius LLP provided legal advice.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AZN $70.07 0.43%
PFE $34.53 1.08%
AAPL $123.25 -0.80%
FB $83.30 0.35%
GOOG $548.34 -1.23%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs